Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells

Journal of Lipid Research

Volumn 46, Issue 6, 2005, Pages 1312-1319

  Lalanne, Florent ^a   Lambert, Gilles ^a   Amar, Marcelo J A ^b   Chétiveaux, Maud ^a   Zaïr, Yassine ^a   Jarnoux, Anne Laure ^a   Ouguerram, Khadija ^a   Friburg, José ^a   Seidah, Nabil G ^c   Brewer Jr , H Bryan ^b   Krempf, Michel ^a   Costet, Philippe ^a  

^a HÔTEL DIEU   (France)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Apolipoprotein B; Low density lipoprotein; Proprotein Convertase Subtilisin Kexin 9

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; SERINE PROTEINASE; UNCLASSIFIED DRUG; CARRIER PROTEIN; LOW DENSITY LIPOPROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PCSK9 PROTEIN, HUMAN; RECOMBINANT PROTEIN; TRIACYLGLYCEROL LIPASE;

ANIMAL CELL; ARTICLE; CELL CULTURE; HUMAN; METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; RNA INTERFERENCE; WILD TYPE; ADENOVIRUS; ANIMAL; C57BL MOUSE; CHEMISTRY; GENE SILENCING; GENETICS; HETEROZYGOTE; IMMUNOBLOTTING; KINETICS; LIPID METABOLISM; LIVER CELL CARCINOMA; MUTATION; PHYSIOLOGY; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; APOLIPOPROTEINS B; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL LINE, TUMOR; CELLS, CULTURED; GENE SILENCING; HETEROZYGOTE; HUMANS; IMMUNOBLOTTING; KINETICS; LIPASE; LIPID METABOLISM; LIPOPROTEINS, LDL; MICE; MICE, INBRED C57BL; MUTATION; PROTEIN BINDING; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SERINE ENDOPEPTIDASES; TIME FACTORS;

EID: 24944466615     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M400396-JLR200     Document Type: Article

References (33)

1. Brown, M. S., and J. L. Goldstein. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science. 232: 34-47.
2. Rader, D. J., J. Cohen, and H. H. Hobbs. 2003. Monogenic hyper-cholesterolemia: new insights in pathogenesis and treatment. J. Clin. Invest. 111: 1795-1803.
3. Soria, L. F., E. H. Ludwig, H. R. Clarke, G. L. Vega, S. M. Grundy, and B. J. McCarthy. 1989. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc. Natl. Acad. Sci. USA. 86: 587-591.
4. Yang, C. Y., S. H. Chen, S. H. Gianturco, W. A. Bradley, J. T. Sparrow, M. Tanimura, W. H. Li, D. A. Sparrow, H. DeLoof, and M. Rosseneu. 1986. Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100. Nature. 323: 738-742.
5. Abifadel, M., M. Varret, J. P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, et al. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34: 154-156.
6. Seidah, N. G., S. Benjannet, L. Wickham, J. Marcinkiewicz, S. B. Jasmin, S. Stifani, A. Basak, A. Prat, and M. Chretien. 2003. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA. 100: 928-933.
7. Seidah, N. G., and M. Chretien. 1999. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res. 848: 45-62.
8. Steiner, D. F. 1998. The proprotein convertases. Curr. Opin. Chem. Biol. 2: 31-39.
9. Zhou, A., G. Webb, X. Zhu, and D. F. Steiner. 1999. Proteolytic processing in the secretory pathway. J. Biol. Chem. 274: 20745-20748.
10. Naureckiene, S., L. Ma, K. Sreekumar, U. Purandare, C. F. Lo, Y. Huang, L. W. Chiang, J. M. Grenier, B. A. Ozenberger, J. S. Jacobsen, et al. 2003. Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch. Biochem. Biophys. 420: 55-67.
11. Maxwell, K. N., R. E. Soccio, E. M. Duncan, E. Sehayek, and J. L. Breslow. 2003. Novel putative SREBP and LXR target genes identi-fied by microarray analysis in liver of cholesterol-fed mice. J. Lipid Res. 44: 2109-2119.
12. Benjannet, S., D. Rhainds, R. Essalmani, J. Mayne, L. Wickham, W. Jin, M. C. Asselin, J. Hamelin, M. Varret, D. Allard, et al. 2004. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279: 48865-48875.
13. Maxwell, K. N., and J. L. Breslow. 2004. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. USA. 101: 7100-7105.
14. Ouguerram, K., M. Chetiveaux, Y. Zair, P. Costet, M. Abifadel, M. Varret, C. Boileau, T. Magot, and M. Krempf. 2004. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler. Thromb. Vasc. Biol. 24: 1448-1453.
15. He, T. C., S. Zhou, L. T. da Costa, J. Yu, K. W. Kinzler, and B. Vogelstein. 1998. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA. 95: 2509-2514.
16. Fromes, Y., A. Salmon, X. Wang, H. Collin, A. Rouche, A. Hagege, K. Schwartz, and M. Y. Fiszman. 1999. Gene delivery to the myocardium by intrapericardial injection. Gene Ther. 6: 683-688.
17. Mc Farlane, A. S. 1958. Efficient trace-labeling of proteins with iodine. Nature. 182: 53-57.
18. Greif, P., M. Wastney, O. Linares, and R. Boston. 1998. Balancing needs, efficiency, and functionality in the provision of modeling software: a perspective of the NIH WinSAAM Project. Adv. Exp. Med. Biol. 445: 3-20.
19. Boisfer, E., G. Lambert, V. Atger, N. Q. Tran, D. Pastier, C. Benetollo, J. F. Trottier, I. Beaucamps, M. Antonucci, M. Laplaud, et al. 1999. Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis. J. Biol. Chem. 274: 11564-11572.
20. Maugeais, C., K. Ouguerram, R. Frenais, P. Maugere, B. Charbonnel, T. Magot, and M. Krempf. 2001. Effect of low-density lipoprotein apheresis on kinetics of apolipoprotein B in heterozygous familial hypercholesterolemia. J. Clin. Endocrinol. Metab. 86: 1679-1686.
21. Lambert, G., M. B. Chase, K. Dugi, A. Bensadoun, H. B. Brewer, Jr., and S. Santamarina-Fojo. 1999. Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor B1. J. Lipid Res. 40: 1294-1303.
22. Iverius, P. H., and J. D. Brunzell. 1985. Human adipose tissue lipoprotein lipase: changes with feeding and relation to postheparin plasma enzyme. Am. J. Physiol. 249: E107-E114.
23. Vaisman, B. L., G. Lambert, M. Amar, C. Joyce, T. Ito, R. D. Shamburek, W. J. Cain, J. Fruchart-Najib, E. D. Neufeld, A. T. Remaley, et al. 2001. ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J. Clin. Invest. 108: 303-309.
24. Higashi, Y., H. Itabe, H. Fukase, M. Mori, Y. Fujimoto, and T. Takano. 2003. Transmembrane lipid transfer is crucial for providing neutral lipids during very low density lipoprotein assembly in endoplasmic reticulum. J. Biol. Chem. 278: 21450-21458.
25. Millar, J. S., C. Maugeais, I. V. Fuki, and D. J. Rader. 2002. Normal production rate of apolipoprotein B in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 22: 989-994.
26. Twisk, J., D. L. Gillian-Daniel, A. Tebon, L. Wang, P. H. Barrett, and A. D. Attie. 2000. The role of the LDL receptor in apolipoprotein B secretion. J. Clin. Invest. 105: 521-532.
27. Attie, A. D. 2004. The mystery of PCSK9. Arterioscler. Thromb. Vasc. Biol. 24: 1337-1339.
28. Letteron, P., A. Sutton, A. Mansouri, B. Fromenty, and D. Pessayre. 2003. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology. 38: 133-140.
29. Schaap, F. G., P. C. Rensen, P. J. Voshol, C. Vrins, H. N. van der Vliet, R. A. Chamuleau, L. M. Havekes, A. K. Groen, and K. W. van Dijk. 2004. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein- triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J. Biol. Chem. 279: 27941-27947.
30. Fruchart-Najib, J., E. Bauge, L. S. Niculescu, T. Pham, B. Thomas, C. Rommens, Z. Majd, B. Brewer, L. A. Pennacchio, and J. C. Fruchart. 2004. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem. Biophys. Res. Commun. 319: 397-404.
31. Park, S. W., Y. A. Moon, and J. D. Horton. 2004. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279: 50630-50638.
32. Cummings, M. H., G. F. Watts, M. Umpleby, T. R. Hennessy, J. R. Quiney, and P. H. Sonksen. 1995. Increased hepatic secretion of verylow-density- lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: a stable isotope study. Atherosclerosis. 113: 79-89.
33. Tremblay, A. J., B. Lamarche, I. L. Ruel, J. C. Hogue, J. Bergeron, C. Gagne, and P. Couture. 2004. Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation. J. Lipid Res. 45: 866-872.